Alyson Yamaguchi
Papers
8
Total Citations
110
H-Index
3
About
Alyson Yamaguchi is pioneering the transformation of drug delivery at Rani Therapeutics, where her work focuses on a revolutionary robotic pill platform designed to replace painful injections for biotherapeutics. Her research addresses a critical unmet need: the oral delivery of large molecules like antibodies, peptides, and hormones, which are typically degraded in the gastrointestinal tract. Yamaguchi’s major contributions include demonstrating that this ingestible robotic pill can safely and reliably deliver biotherapeutics with bioavailability comparable to traditional injections. Her landmark 2021 study on the pill’s safety and tolerability in healthy subjects (94 citations) laid the groundwork for subsequent breakthroughs, including the successful oral delivery of teriparatide for osteoporosis and an ustekinumab biosimilar. She has also shown proof-of-concept for delivering follicle-stimulating hormone and GLP-1 agonists, opening doors for more patient-friendly treatments for chronic conditions. With multiple Phase 1 studies and conference presentations, Yamaguchi’s work is redefining patient compliance, offering hope to millions who dread daily injections for diseases ranging from osteoporosis to diabetes.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8